長時間作用型PEG-rhG-CSF市場レポート：動向、予測、競合分析 (2031年まで)

世界の長時間作用型PEG-rhG-CSF市場の将来性は有望で、腫瘍性疾患と血液疾患に機会があります。世界の長時間作用型PEG-rhG-CSF市場は、2025年から2031年にかけてCAGR 6.8％で成長すると予想されます。この市場の主な促進要因は、がんの有病率の上昇、長時間作用型生物製剤への嗜好の高まり、バイオシミラーの利用可能性の増加です。

• Lucintelの予測では、種類別ではジェネリック医薬品が予測期間中に高い成長を遂げる見込みです。
• 用途別では、腫瘍性疾患が高い成長を遂げると予想されます。
• 地域別では、アジア太平洋が予測期間中に最も高い成長が見込まれます。

長時間作用型PEG-rhG-CSF市場の新たな動向

長時間作用型PEG-rhG-CSF市場は、バイオ医薬品、医療経済、がん治療における患者中心の治療戦略におけるパラダイムの変化を反映する多くの重要な動向の影響下にあります。

• バイオシミラーの支配と価格侵食：最も強い動向は、ペグフィルグラスチムのバイオシミラーによる市場シェアの拡大です。さらなるバイオシミラーが市場に参入し、世界中で承認されれば、価格競争が激化し、医療システムに大幅なコスト削減をもたらし、この重要な支持療法薬への患者アクセスを拡大する可能性があります。
• 患者の利便性と自己投与の重視：ペグフィルグラスチムには、患者の利便性を考慮した投与システムを構築し、使用する傾向が強まっています。安全性を向上させた自動注射器システムやプレフィルドシリンジはますます普及しており、患者に利便性を提供し、通院頻度を最小限に抑え、特に外来環境では治療レジメンのコンプライアンスを高める可能性があります。
• 価値と費用対効果の実証の重視：医療費が高騰する中、長時間作用型PEG-rhG-CSFの費用対効果や価値を証明することは、特に短時間作用型G-CSFや、化学療法による好中球減少症や関連合併症（発熱性好中球減少症や入院など）の治療費との関係において、非常に重要です。
• 個別化投与アプローチ：最近のエビデンスでは、ペグフィルグラスチムの一様な投与量がすべての人にとって最良ではない可能性が強調されています。効率を最大化し、副作用を最小化するために、体重、体表面積、個々の化学療法レジメンなどの患者特異的パラメータを用いた個別化投与アプローチを調査する動きがあります。
• がん治療全般のパスウェイへの統合：長時間作用型PEG-rhG-CSFは、化学療法誘発性好中球減少症に対する適切かつタイムリーな予防が提供され、がん患者の全体的な管理および転帰の改善につながるように、がん治療全体のパスウェイおよび治療推奨にますます組み込まれるようになってきています。

このような動向は、バイオシミラー競争による価格の引き下げ、新しいデリバリーアプローチによる患者の利便性の向上、治療の経済的価値の強調、より個別化された治療戦略の検討、そして日常的ながん治療の実践へのシームレスな統合によって、長時間作用型PEG-rhG-CSF市場に変革をもたらしつつあります。

長時間作用型PEG-rhG-CSF市場の最近の動向

長時間作用型PEG-rhG-CSF市場には、その継続的な変貌と支持的がん治療への影響力を浮き彫りにする重要な新興国市場の発展が数多く見られます。

• 複数のバイオシミラー製品の商業化と開発の成功：主な発展のひとつは、ペグフィルグラスチムのバイオシミラー製剤がいくつか開発され、規制当局の承認を得て、主要な製薬市場で上市されたことです。これは、オリジネーターブランドに絶大な競合をもたらし、価格引き下げの主な原動力となっています。
• 医療専門家によるバイオシミラーの持続的受容と普及：ペグフィルグラスチムバイオシミラーは、基準製剤と同様の有効性と安全性プロファイルを有しているため、医療専門家による処方への慣れと安心感が高まっています。バイオシミラー製剤の市場浸透が促進されつつあります。
• 患者の利便性を高めるドラッグデリバリー技術の革新：製薬会社は、安全機構付きプレフィルドシリンジや自動注射ペンなど、ペグフィルグラスチムの使いやすいドラッグデリバリー技術の開発と導入に注力してきました。これらの技術革新は、投与を簡便化し、患者の使用感を向上させることを目的としています。
• バイオシミラーの使用を支持する実臨床エビデンスの増加：日常臨床におけるペグフィルグラスチムバイオシミラーの有効性と安全性を証明するリアルワールドエビデンス（実臨床試験）の報告が増え、処方者と患者の信頼が高まっています。
• 度重なる特許切れとバイオシミラーの新規参入：重要なペグフィルグラスチム製剤の特許満了が続くことにより、バイオシミラーの新規参入の門戸が開かれ、市場競争が激化し、価格が下がる可能性があります。

これらの進歩は、バイオシミラーを使用することで、より手頃な価格で入手しやすくなり、高度なデリバリーシステムにより患者への投与が容易になり、バイオシミラーの安全性と有効性に関する確固たるエビデンスベースが確立され、市場競争が激化することで、長時間作用型PEG-rhG-CSF市場に影響を与えています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

• 背景と分類
• サプライチェーン

第3章 市場動向と予測分析

• マクロ経済の動向と予測
• 業界の促進要因と課題
• PESTLE分析
• 特許分析
• 規制環境

第4章 世界の長時間作用型PEG-rhG-CSF市場：種類別

• 概要
• 魅力分析：種類別
• 革新的医薬品：動向と予測（2019～2031年）
• ジェネリック医薬品：動向と予測（2019～2031年）

第5章 世界の長時間作用型PEG-rhG-CSF市場：用途別

• 概要
• 魅力分析：用途別
• 腫瘍性疾患：動向と予測（2019～2031年）
• 血液疾患：動向と予測（2019～2031年）
• その他：動向と予測（2019～2031年）

第6章 地域分析

• 概要
• 世界の長時間作用型PEG-rhG-CSF市場：地域別

第7章 北米の長時間作用型PEG-rhG-CSF市場

• 概要
• 北米の長時間作用型PEG-rhG-CSF市場：種類別
• 北米の長時間作用型PEG-rhG-CSF市場：用途別
• 米国の長時間作用型PEG-rhG-CSF市場
• メキシコの長時間作用型PEG-rhG-CSF市場
• カナダの長時間作用型PEG-rhG-CSF市場

第8章 欧州における長時間作用型PEG-rhG-CSF市場

• 概要
• 欧州の長時間作用型PEG-rhG-CSF市場：種類別
• 欧州の長時間作用型PEG-rhG-CSF市場：用途別
• ドイツの長時間作用型PEG-rhG-CSF市場
• フランスの長時間作用型PEG-rhG-CSF市場
• スペインの長時間作用型PEG-rhG-CSF市場
• イタリアの長時間作用型PEG-rhG-CSF市場
• 英国の長時間作用型PEG-rhG-CSF市場

第9章 アジア太平洋の長時間作用型PEG-rhG-CSF市場

• 概要
• アジア太平洋の長時間作用型PEG-rhG-CSF市場：種類別
• アジア太平洋の長時間作用型PEG-rhG-CSF市場：用途別
• 日本の長時間作用型PEG-rhG-CSF市場
• インドの長時間作用型PEG-rhG-CSF市場
• 中国の長時間作用型PEG-rhG-CSF市場
• 韓国の長時間作用型PEG-rhG-CSF市場
• インドネシアの長時間作用型PEG-rhG-CSF市場

第10章 その他の地域 (ROW) の長時間作用型PEG-rhG-CSF市場

• 概要
• その他の地域 (ROW) の長時間作用型PEG-rhG-CSF市場：種類別
• その他の地域 (ROW) の長時間作用型PEG-rhG-CSF市場：用途別
• 中東の長時間作用型PEG-rhG-CSF市場
• 南米の長時間作用型PEG-rhG-CSF市場
• アフリカの長時間作用型PEG-rhG-CSF市場

第11章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析
  • 競争企業間の敵対関係
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
• 市場シェア分析

第12章 機会と戦略分析

• バリューチェーン分析
• 成長機会分析
  • 成長機会：種類別
  • 成長機会：用途別
• 世界の長時間作用型PEG-rhG-CSF市場の新たな動向
• 戦略分析
  • 新製品開発
  • 認証・ライセンシング
  • 企業合併・買収 (M&A) 、契約、提携、合弁事業

第13章 バリューチェーン上の主要企業のプロファイル

• 競合分析
• Amgen
• Pfizer
• Mylan
• Sandoz
• Biocon Biologics
• Coherus BioSciences
• Fresenius Kabi
• CSPC
• Qilu Pharmaceutical
• Jiangsu Hengrui Medicine

第14章 付録

• 図の一覧
• 表の一覧
• 分析手法
• 免責事項
• 著作権
• 略語と技術単位
• Lucintelについて
• お問い合わせ

List of Figures

• Figure 1.1: Trends and Forecast for the Global Long-acting PEG-rhG-CSF Market
• Figure 2.1: Usage of Long-acting PEG-rhG-CSF Market
• Figure 2.2: Classification of the Global Long-acting PEG-rhG-CSF Market
• Figure 2.3: Supply Chain of the Global Long-acting PEG-rhG-CSF Market
• Figure 2.4: Driver and Challenges of the Long-acting PEG-rhG-CSF Market
• Figure 3.1: Trends of the Global GDP Growth Rate
• Figure 3.2: Trends of the Global Population Growth Rate
• Figure 3.3: Trends of the Global Inflation Rate
• Figure 3.4: Trends of the Global Unemployment Rate
• Figure 3.5: Trends of the Regional GDP Growth Rate
• Figure 3.6: Trends of the Regional Population Growth Rate
• Figure 3.7: Trends of the Regional Inflation Rate
• Figure 3.8: Trends of the Regional Unemployment Rate
• Figure 3.9: Trends of Regional Per Capita Income
• Figure 3.10: Forecast for the Global GDP Growth Rate
• Figure 3.11: Forecast for the Global Population Growth Rate
• Figure 3.12: Forecast for the Global Inflation Rate
• Figure 3.13: Forecast for the Global Unemployment Rate
• Figure 3.14: Forecast for the Regional GDP Growth Rate
• Figure 3.15: Forecast for the Regional Population Growth Rate
• Figure 3.16: Forecast for the Regional Inflation Rate
• Figure 3.17: Forecast for the Regional Unemployment Rate
• Figure 3.18: Forecast for Regional Per Capita Income
• Figure 4.1: Global Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
• Figure 4.2: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Type
• Figure 4.3: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Type
• Figure 4.4: Trends and Forecast for Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 4.5: Trends and Forecast for Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 5.1: Global Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
• Figure 5.2: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Application
• Figure 5.3: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Application
• Figure 5.4: Trends and Forecast for Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 5.5: Trends and Forecast for Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 5.6: Trends and Forecast for Others in the Global Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 6.1: Trends of the Global Long-acting PEG-rhG-CSF Market ($B) by Region (2019-2024)
• Figure 6.2: Forecast for the Global Long-acting PEG-rhG-CSF Market ($B) by Region (2025-2031)
• Figure 7.1: Trends and Forecast for the North American Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 7.2: North American Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
• Figure 7.3: Trends of the North American Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
• Figure 7.4: Forecast for the North American Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
• Figure 7.5: North American Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
• Figure 7.6: Trends of the North American Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
• Figure 7.7: Forecast for the North American Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
• Figure 7.8: Trends and Forecast for the United States Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 7.9: Trends and Forecast for the Mexican Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 7.10: Trends and Forecast for the Canadian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 8.1: Trends and Forecast for the European Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 8.2: European Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
• Figure 8.3: Trends of the European Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
• Figure 8.4: Forecast for the European Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
• Figure 8.5: European Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
• Figure 8.6: Trends of the European Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
• Figure 8.7: Forecast for the European Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
• Figure 8.8: Trends and Forecast for the German Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 8.9: Trends and Forecast for the French Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 8.10: Trends and Forecast for the Spanish Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 8.11: Trends and Forecast for the Italian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 8.12: Trends and Forecast for the United Kingdom Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 9.1: Trends and Forecast for the APAC Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 9.2: APAC Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
• Figure 9.3: Trends of the APAC Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
• Figure 9.4: Forecast for the APAC Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
• Figure 9.5: APAC Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
• Figure 9.6: Trends of the APAC Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
• Figure 9.7: Forecast for the APAC Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
• Figure 9.8: Trends and Forecast for the Japanese Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 9.9: Trends and Forecast for the Indian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 9.10: Trends and Forecast for the Chinese Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 9.11: Trends and Forecast for the South Korean Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 9.12: Trends and Forecast for the Indonesian Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 10.1: Trends and Forecast for the ROW Long-acting PEG-rhG-CSF Market (2019-2031)
• Figure 10.2: ROW Long-acting PEG-rhG-CSF Market by Type in 2019, 2024, and 2031
• Figure 10.3: Trends of the ROW Long-acting PEG-rhG-CSF Market ($B) by Type (2019-2024)
• Figure 10.4: Forecast for the ROW Long-acting PEG-rhG-CSF Market ($B) by Type (2025-2031)
• Figure 10.5: ROW Long-acting PEG-rhG-CSF Market by Application in 2019, 2024, and 2031
• Figure 10.6: Trends of the ROW Long-acting PEG-rhG-CSF Market ($B) by Application (2019-2024)
• Figure 10.7: Forecast for the ROW Long-acting PEG-rhG-CSF Market ($B) by Application (2025-2031)
• Figure 10.8: Trends and Forecast for the Middle Eastern Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 10.9: Trends and Forecast for the South American Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 10.10: Trends and Forecast for the African Long-acting PEG-rhG-CSF Market ($B) (2019-2031)
• Figure 11.1: Porter's Five Forces Analysis of the Global Long-acting PEG-rhG-CSF Market
• Figure 11.2: Market Share (%) of Top Players in the Global Long-acting PEG-rhG-CSF Market (2024)
• Figure 12.1: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Type
• Figure 12.2: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Application
• Figure 12.3: Growth Opportunities for the Global Long-acting PEG-rhG-CSF Market by Region
• Figure 12.4: Emerging Trends in the Global Long-acting PEG-rhG-CSF Market

List of Tables

• Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Long-acting PEG-rhG-CSF Market by Type and Application
• Table 1.2: Attractiveness Analysis for the Long-acting PEG-rhG-CSF Market by Region
• Table 1.3: Global Long-acting PEG-rhG-CSF Market Parameters and Attributes
• Table 3.1: Trends of the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 3.2: Forecast for the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 4.1: Attractiveness Analysis for the Global Long-acting PEG-rhG-CSF Market by Type
• Table 4.2: Market Size and CAGR of Various Type in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 4.3: Market Size and CAGR of Various Type in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 4.4: Trends of Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 4.5: Forecast for Innovative Drugs in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 4.6: Trends of Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 4.7: Forecast for Generic Drugs in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 5.1: Attractiveness Analysis for the Global Long-acting PEG-rhG-CSF Market by Application
• Table 5.2: Market Size and CAGR of Various Application in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 5.3: Market Size and CAGR of Various Application in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 5.4: Trends of Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 5.5: Forecast for Neoplastic Diseases in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 5.6: Trends of Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 5.7: Forecast for Blood Disorders in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 5.8: Trends of Others in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 5.9: Forecast for Others in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 6.1: Market Size and CAGR of Various Regions in the Global Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 6.2: Market Size and CAGR of Various Regions in the Global Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 7.1: Trends of the North American Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 7.2: Forecast for the North American Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 7.3: Market Size and CAGR of Various Type in the North American Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 7.4: Market Size and CAGR of Various Type in the North American Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 7.5: Market Size and CAGR of Various Application in the North American Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 7.6: Market Size and CAGR of Various Application in the North American Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 7.7: Trends and Forecast for the United States Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 7.8: Trends and Forecast for the Mexican Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 7.9: Trends and Forecast for the Canadian Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 8.1: Trends of the European Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 8.2: Forecast for the European Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 8.3: Market Size and CAGR of Various Type in the European Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 8.4: Market Size and CAGR of Various Type in the European Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 8.5: Market Size and CAGR of Various Application in the European Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 8.6: Market Size and CAGR of Various Application in the European Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 8.7: Trends and Forecast for the German Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 8.8: Trends and Forecast for the French Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 8.9: Trends and Forecast for the Spanish Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 8.10: Trends and Forecast for the Italian Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 8.11: Trends and Forecast for the United Kingdom Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 9.1: Trends of the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 9.2: Forecast for the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 9.3: Market Size and CAGR of Various Type in the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 9.4: Market Size and CAGR of Various Type in the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 9.5: Market Size and CAGR of Various Application in the APAC Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 9.6: Market Size and CAGR of Various Application in the APAC Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 9.7: Trends and Forecast for the Japanese Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 9.8: Trends and Forecast for the Indian Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 9.9: Trends and Forecast for the Chinese Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 9.10: Trends and Forecast for the South Korean Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 9.11: Trends and Forecast for the Indonesian Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 10.1: Trends of the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 10.2: Forecast for the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 10.3: Market Size and CAGR of Various Type in the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 10.4: Market Size and CAGR of Various Type in the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 10.5: Market Size and CAGR of Various Application in the ROW Long-acting PEG-rhG-CSF Market (2019-2024)
• Table 10.6: Market Size and CAGR of Various Application in the ROW Long-acting PEG-rhG-CSF Market (2025-2031)
• Table 10.7: Trends and Forecast for the Middle Eastern Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 10.8: Trends and Forecast for the South American Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 10.9: Trends and Forecast for the African Long-acting PEG-rhG-CSF Market (2019-2031)
• Table 11.1: Product Mapping of Long-acting PEG-rhG-CSF Suppliers Based on Segments
• Table 11.2: Operational Integration of Long-acting PEG-rhG-CSF Manufacturers
• Table 11.3: Rankings of Suppliers Based on Long-acting PEG-rhG-CSF Revenue
• Table 12.1: New Product Launches by Major Long-acting PEG-rhG-CSF Producers (2019-2024)
• Table 12.2: Certification Acquired by Major Competitor in the Global Long-acting PEG-rhG-CSF Market

The future of the global long-acting PEG-rhG-CSF market looks promising with opportunities in the neoplastic disease and blood disorder markets. The global long-acting PEG-rhG-CSF market is expected to grow with a CAGR of 6.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of cancer, the growing preference for long-acting biologics, and the increasing availability of biosimilars.

• Lucintel forecasts that, within the type category, generic drugs are expected to witness higher growth over the forecast period.
• Within the application category, neoplastic disease is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market is under the impact of a number of important trends that mirror changing paradigms in biopharmaceuticals, healthcare economics, and patient-centered treatment strategies in oncology.

• Biosimilar Domination and Price Erosion: The strongest trend is the growing market share gain experienced by biosimilar versions of pegfilgrastim. With additional biosimilars entering the market and securing regulatory approval across the world, price competition will strengthen, causing substantial cost savings to healthcare systems and possibly expanding patient access to this critical supportive care drug.
• Focus on Patient Convenience and Self-Administration: There is an increasing trend towards the creation and use of patient-convenient administration systems for pegfilgrastim. Auto-injector systems and pre-filled syringes with improved safety features are becoming increasingly popular, providing patients with more convenience, minimizing the frequency of clinic visits, and potentially enhancing compliance with the treatment regimen, especially in the outpatient environment.
• Emphasis on Value and Cost-Effectiveness Demonstration: As costs of healthcare rise, there is great stress on proving the cost-effectiveness and value of Long-acting PEG-rhG-CSF, particularly in relation to shorter-acting G-CSFs and the expense of treating chemotherapy-induced neutropenia and related complications, e.g., febrile neutropenia and hospitalization.
• Personalized Dosing Approaches: Recent evidence is highlighting that one uniform dose of pegfilgrastim might not be the best for everyone. There is a move towards researching individualized dosing approaches by using patient-specific parameters such as body weight, body surface area, and individual chemotherapy regimens in an effort to maximize efficiency and minimize side effects.
• Integration into Overall Cancer Care Pathways: Long-acting PEG-rhG-CSF is being increasingly integrated into overall cancer care pathways and treatment recommendations so that appropriate and timely prophylaxis against chemotherapy-induced neutropenia is provided, leading to improved overall management of and outcomes in patients with cancer.

These trends are transforming the Long-acting PEG-rhG-CSF market by reducing prices through biosimilar competition, improving patient convenience with newer delivery approaches, highlighting the economic value of the therapy, looking at more individualized treatment strategies, and integrating it seamlessly into routine cancer care practices.

Recent Developments in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market has seen a number of critical developments that highlight its continued transformation and influence on supportive cancer care.

• Successful Commercialization and Development of Several Biosimilar Products: One of the major developments is that several biosimilar versions of pegfilgrastim have been successfully developed, approved by the regulatory authorities, and launched across key pharma markets. This has brought immense competition to the originator brand and has been a primary driver of price cuts.
• Sustained Acceptance and Uptake of Biosimilars by Healthcare Professionals: With time, healthcare professionals have grown more accustomed and comfortable prescribing pegfilgrastim biosimilars, aware of their similar efficacy and safety profiles with the reference product. Sustained acceptance has promoted enhanced market penetration of biosimilars.
• Innovation in Drug Delivery Technologies for Patient Convenience: Pharmaceutical companies have focused on developing and implementing user-friendly drug delivery technologies for pegfilgrastim, such as pre-filled syringes with safety mechanisms and auto-injector pens. These innovations aim to simplify administration and improve the patient experience.
• Increasing Body of Real-World Evidence in Support of Use of Biosimilars: More real-world evidence studies are being reported documenting the efficacy and safety of pegfilgrastim biosimilars in everyday clinical practice, continuing to build prescriber and patient confidence.
• Repeated Expiration of Patents and New Biosimilar Players: Continued expiration of patents on important pegfilgrastim products continues to open the doors for new biosimilar players to come into the market, adding more competition and possibly pushing prices lower.

These advances are affecting the Long-acting PEG-rhG-CSF market by making it more affordable and accessible using biosimilars, making administration easier for patients with advanced delivery systems, establishing a robust evidence base for biosimilar safety and efficacy, and creating a more competitive market setting.

Strategic Growth Opportunities in the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, although mainly developed for the prevention of chemotherapy-induced neutropenia, has a number of strategic growth opportunities across key applications in oncology and hematology.

• Increasing Prophylactic Application in Moderate-Risk Chemotherapy Regimens: Pegfilgrastim is usually recommended by current guidelines for high-risk regimens. An emerging opportunity exists with the identification and expansion of its prophylactic application in certain moderate-risk regimens where the cost may be offset by the benefit of avoiding neutropenic complications, especially given the availability of biosimilars at lower costs.
• Tapering Dosing Strategies in Special Patient Populations: Studies on patient-specific dosing based on various factors like body weight, age, and comorbidities can result in more effective and cost-conscious utilization of pegfilgrastim among such patient groups, offering a future growth opportunity through resource optimization.
• Investigating Use with Next-Generation Cancer Therapies: With each new myelosuppressive cancer therapy introduced, such as targeted therapies and immunotherapies, integrated into treatment combinations, there might be an escalating demand for prophylactic pegfilgrastim to alleviate related neutropenia, constituting a strategic growth opportunity.
• Growing Adoption in Emerging Economies with Value Biosimilars: Availability of lower-priced biosimilar equivalents of pegfilgrastim presents a big growth opportunity to increase access to this critical supportive care in emerging economies where price can be an important obstacle to treatment. Distribution networks and partnership strategies will play a key role.
• Examining Use in Hematopoietic Stem Cell Transplant: Although mostly utilized in chemotherapy-induced neutropenia, the potential use of pegfilgrastim in hematopoietic stem cell mobilization can be studied further and optimized and may widen its use in transplantation.

Profiting from such strategic expansion opportunities demands constant clinical research to streamline treatment protocols and determine new uses, manufacturing specific dosing strategies and preparations, as well as successful market access tactics, especially for biosimilars in underdeveloped areas.

Long-acting PEG-rhG-CSF Market Driver and Challenges

The Long-acting PEG-rhG-CSF market is affected by an intricate interrelationship of drivers and challenges emanating from clinical demand, technological development, economic pressures, and regulatory frameworks controlling biopharmaceuticals.

The factors responsible for driving the long-acting PEG-rhG-CSF market include:

1. Established efficacy in prevention of chemotherapy-induced neutropenia: The strong clinical evidence that proves the efficacy of pegfilgrastim in the prevention of the incidence and severity of neutropenia continues to be the major reason for its application in patients undergoing myelosuppressive chemotherapy.

2. Growing global prevalence of cancer and chemotherapy use: The increasing global cancer burden and the persistent use of chemotherapy as an important treatment strategy guarantee an ongoing demand for supportive treatments such as pegfilgrastim.

3. Increasing availability and acceptance of biosimilars: Increased numbers of approved and commercially available pegfilgrastim biosimilars offer lower-cost treatment alternatives, increasing market access and overall market volume.

4. Convenience and friendly patient delivery device development: The availability and usage of auto-injectors increase patient convenience and compliance, further enhancing pegfilgrastim usage, especially among outpatients.

5. Reimbursement policy and supportive clinical practice guidelines: Favorable reimbursement policies in most healthcare systems and recommendations of oncology organizations allow the utilization of pegfilgrastim in suitable clinical practice settings.

Challenges in the long-acting PEG-rhG-CSF market are:

1. Increasing price competition from biosimilars: The rise in the number of biosimilar entrants creates huge price erosion, affecting the profitability and revenues of both biosimilar and originator manufacturers.

2. Optimal patient selection and personalized dosing: Who to treat and how much pegfilgrastim to give them remain subjects for ongoing investigation and optimization.

3. Coping with the cost burden on healthcare systems: Even in the presence of biosimilars, overall supportive cancer care costs, including pegfilgrastim, continue to pose a challenge for healthcare payers and systems around the world.

In summary, the Long-acting PEG-rhG-CSF market is fueled by its proven efficacy, the mounting demand for neutropenia treatment because of the rising burden of cancer globally, the availability of cheaper biosimilars, and improved delivery device advancements. Nevertheless, the market is challenged by heightening price competition, the demand for individually customized treatment strategies, and the sheer cost burden on healthcare systems.

List of Long-acting PEG-rhG-CSF Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leveraging integration opportunities across the value chain. With these strategies, long-acting PEG-rhG-CSF companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the long-acting PEG-rhG-CSF companies profiled in this report include:

• Amgen
• Pfizer
• Mylan
• Sandoz
• Biocon Biologics
• Coherus BioSciences
• Fresenius Kabi
• CSPC
• Qilu Pharmaceutical
• Jiangsu Hengrui Medicine

Long-acting PEG-rhG-CSF Market by Segment

The study includes a forecast for the global long-acting PEG-rhG-CSF market by type, application, and region.

Long-acting PEG-rhG-CSF Market by Type [Value from 2019 to 2031]:

• Innovative Drugs
• Generic Drugs

Long-acting PEG-rhG-CSF Market by Application [Value from 2019 to 2031]:

• Neoplastic Diseases
• Blood Disorders
• Others

Long-acting PEG-rhG-CSF Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Long-acting PEG-rhG-CSF Market

The Long-acting PEG-rhG-CSF market, a cornerstone of supportive cancer care, continues to evolve with a strong emphasis on biosimilar competition and enhanced patient convenience. Designed to reduce the incidence of chemotherapy-induced neutropenia with less frequent dosing than short-acting G-CSFs, pegfilgrastim has become a standard of care. Recent developments are characterized by the increasing availability and uptake of biosimilar versions, driving price adjustments and expanding patient access globally. Delivery device innovations, including pre-filled syringes and auto-injectors, are also significantly contributing to defining market trends in various regions.

• United States: Significant biosimilar erosion has occurred within the US Long-acting PEG-rhG-CSF market, driving considerable cost savings for patients and healthcare providers alike. Recent changes have involved the ongoing introduction of new biosimilars, as well as fierce price wars between manufacturers. The emphasis lies in balancing affordability with maintaining a consistent level of access to this critical supportive treatment for patients on myelosuppressive chemotherapy.
• China: China's market for Long-acting PEG-rhG-CSF is experiencing swift growth, fueled by an expanding cancer patient base and rising uptake of sophisticated cancer therapies. Developments in the recent past include the approval and launch of multiple locally manufactured pegfilgrastim biosimilars. The biosimilars are reducing the cost of therapy and making it more accessible, driving strong market growth and greater competition with the reference product.
• Germany: The German healthcare system has easily adopted biosimilar forms of Long-acting PEG-rhG-CSF, leading to significant cost savings. Recent advancements include a high level of biosimilar prescribing, fueled by positive reimbursement policies and physician acceptance. The market focuses on guaranteeing the quality and effectiveness of biosimilars while maximizing healthcare spending for supportive cancer care.
• India: Long-acting PEG-rhG-CSF in India is marked by rising affordability and accessibility, which is mainly attributed to the availability of a number of local biosimilar producers. Recent trends encompass greater usage of these economic alternatives in both public and private sectors. Measures are being taken to implement strict quality control and increase access across the nation.
• Japan: Japan's market for Long-acting PEG-rhG-CSF is witnessing a slow but consistent rise in the adoption of biosimilars. Recent events include cautious assessment of the safety and performance of biosimilar products by regulators and healthcare professionals. Although the rate of adoption is relatively conservative, cost-containment pressures are likely to propel more biosimilar penetration in the next few years.

Features of the Global Long-acting PEG-rhG-CSF Market

• Market Size Estimates: Long-acting PEG-rhG-CSF market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Long-acting PEG-rhG-CSF market size by type, application, and region in terms of value ($B).
• Regional Analysis: Long-acting PEG-rhG-CSF market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the long-acting PEG-rhG-CSF market.
• Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the long-acting PEG-rhG-CSF market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the long-acting PEG-rhG-CSF market by type (innovative drugs and generic drugs), application (neoplastic diseases, blood disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Long-acting PEG-rhG-CSF Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Innovative Drugs: Trends and Forecast (2019-2031)
• 4.4 Generic Drugs: Trends and Forecast (2019-2031)

5. Global Long-acting PEG-rhG-CSF Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Neoplastic Diseases: Trends and Forecast (2019-2031)
• 5.4 Blood Disorders: Trends and Forecast (2019-2031)
• 5.5 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Long-acting PEG-rhG-CSF Market by Region

7. North American Long-acting PEG-rhG-CSF Market

• 7.1 Overview
• 7.2 North American Long-acting PEG-rhG-CSF Market by Type
• 7.3 North American Long-acting PEG-rhG-CSF Market by Application
• 7.4 United States Long-acting PEG-rhG-CSF Market
• 7.5 Mexican Long-acting PEG-rhG-CSF Market
• 7.6 Canadian Long-acting PEG-rhG-CSF Market

8. European Long-acting PEG-rhG-CSF Market

• 8.1 Overview
• 8.2 European Long-acting PEG-rhG-CSF Market by Type
• 8.3 European Long-acting PEG-rhG-CSF Market by Application
• 8.4 German Long-acting PEG-rhG-CSF Market
• 8.5 French Long-acting PEG-rhG-CSF Market
• 8.6 Spanish Long-acting PEG-rhG-CSF Market
• 8.7 Italian Long-acting PEG-rhG-CSF Market
• 8.8 United Kingdom Long-acting PEG-rhG-CSF Market

9. APAC Long-acting PEG-rhG-CSF Market

• 9.1 Overview
• 9.2 APAC Long-acting PEG-rhG-CSF Market by Type
• 9.3 APAC Long-acting PEG-rhG-CSF Market by Application
• 9.4 Japanese Long-acting PEG-rhG-CSF Market
• 9.5 Indian Long-acting PEG-rhG-CSF Market
• 9.6 Chinese Long-acting PEG-rhG-CSF Market
• 9.7 South Korean Long-acting PEG-rhG-CSF Market
• 9.8 Indonesian Long-acting PEG-rhG-CSF Market

10. ROW Long-acting PEG-rhG-CSF Market

• 10.1 Overview
• 10.2 ROW Long-acting PEG-rhG-CSF Market by Type
• 10.3 ROW Long-acting PEG-rhG-CSF Market by Application
• 10.4 Middle Eastern Long-acting PEG-rhG-CSF Market
• 10.5 South American Long-acting PEG-rhG-CSF Market
• 10.6 African Long-acting PEG-rhG-CSF Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Long-acting PEG-rhG-CSF Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Amgen
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Pfizer
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Mylan
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Sandoz
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Biocon Biologics
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Coherus BioSciences
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Fresenius Kabi
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 CSPC
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Qilu Pharmaceutical
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Jiangsu Hengrui Medicine
  • Company Overview
  • Long-acting PEG-rhG-CSF Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us